透過您的圖書館登入
IP:18.225.117.183
  • 學位論文

探討晚期子宮頸癌不同治療方式之成本效益分析

Cost-effectiveness analysis of treatments for late stage cervical cancer

指導教授 : 李亞欣

摘要


目的:本研究將利用健保資料庫,探討晚期子宮頸癌病患於不同治療方式下之存活率、醫療費用與治療成本效益之差別。 方法:本研究母群體資料取自於衛生福利部統計處之健康資料加值應用協作中心健保資料庫,研究對象為2007年至2009年新增之晚期子宮頸癌病患共1,274人,依據不同治療方式將子宮頸癌病患分為三組(手術治療共890人、CCRT治療共59人、手術後CCRT治療共297人),本研究利用統計套裝軟體SPSS 20.0 for windows進行資料處理,進行描述性統計及推論性統計,應用複迴歸分析瞭解影響晚期子宮頸癌醫療總費用及成本效益之相關因素,並運用Cox對比涉險模式進行存活分析,並計算風險率,進一步瞭解影響晚期子宮頸癌患者是否死亡之相關因素。 結果:2007年至2009年共有1,274位晚期子宮頸癌病患,手術治療病患平均存活天數為631.61天,平均醫療費用為231,748.37元,平均成本效益為838.44(元/天),CCRT治療病患平均存活天數為578.90天,平均醫療費用為375,023.07元,平均成本效益為1,594.58(元/天),手術後CCRT治療病患平均存活天數為617.63天,平均醫療費用為315,622.01元,平均成本效益為734.01(元/天),其中居住地都市化程度及腫瘤期別為影響晚期子宮頸癌成本效益之相關因素。 結論:本研究得知以手術後CCRT治療之成本效益最佳,其次為手術治療,成本效益最差的為CCRT治療。

並列摘要


Objectives: This study was conducted from the registered Taiwan National Health Insurance database. To understanding the difference of survival rate, cost-effectiveness on medical expenses of treatments for late stage cervical cancer patients. Methods: In this study, the population conducted from the registered Taiwan National Health Insurance database. All new late stage cervical cancer in Taiwan diagnosed between years 2007 to 2011 were included in the study, total with 1,274 cases. According to treatments will be divided into three groups (Surgical treatment patient is 890 cases, CCRT therapy is 59 cases, CCRT therapy after surgery is 297 cases). This study use IBM SPSS Statistics 20.0 (for windows) to do descriptive statistics and inferential statistics. Using Multiple regression analysis to understanding of the relevant factors for late stage cervical cancer in the medical expenses and cost-effectiveness. And use Cox Proportional Hazards Model to do survival analysis, and calculate the Hazard Ratio. Learn more about the factors that influence whether patients died of late stage cervical cancer. Results: Total of late stage cervical cancer patient is 1,274 cases in 2007 to 2009. Surgical treatment of patients with average of survival days is 631.61 days, the average medical expenses is NT 231,748.37, the average of cost-effectiveness is 838.44 (cost/day). CCRT therapy of patients with average of survival days is 578.90 days, the average medical expenses is NT 375,023.07, the, the average of cost-effectiveness is 1,594.58 (cost/day). CCRT therapy after surgery of patients with average of survival days is 617.63 days, the average medical expenses is NT 315,622.01, the average of cost-effectiveness is 734.01 (cost/day). Level of the inhabited area and tumor stage are the factors that influence late stage cervical cancer in cost-effectiveness. Conclusion: The study found that CCRT therapy after surgery treatment has the lowest cost-effectiveness. The second is the surgical treatment. CCRT therapy has the highest cost-effectiveness.

參考文獻


1. 王乃弘(1999)。民眾就醫選擇之研究—分析層級程序法之應用。中華公共衛生雜誌,18(2),138-151。
6. 行政院衛生福利部國民健康署(2011)。中華民國100年癌症登記報告,台北。
10. 吳肖琪、簡麗年、吳義勇(2004)。探討術前合併症指標與醫療利用及手術結果之關聯性—以全股(髖)關節置換健保申報資料為例。台灣衛誌,3,121-129。
11. 吳岱穎、郭冠良、陳建志、林光洋、黃惠娟(2004)。子宮頸癌的篩檢。基層醫學,19(12),288-295。
13. 吳香達(2003)。子宮頸癌治療系列報導—壹、手術治療。中華民國婦癌醫學雜誌,1,2-22。

延伸閱讀